Prediction of ESRD and Death Among People With CKD: The Chronic Renal Impairment in Birmingham (CRIB) Prospective Cohort Study

Background Validated prediction scores are required to assess the risks of end-stage renal disease (ESRD) and death in individuals with chronic kidney disease (CKD). Study Design Prospective cohort study with validation in a separate cohort. Setting & Participants Cox regression was used to assess the relevance of baseline characteristics to risk of ESRD (mean follow-up, 4.1 years) and death (mean follow-up, 6.0 years) in 382 patients with stages 3-5 CKD not initially on dialysis therapy in the Chronic Renal Impairment in Birmingham (CRIB) Study. Resultant risk prediction equations were tested in a separate cohort of 213 patients with CKD (the East Kent cohort). Factors 44 baseline characteristics (including 30 blood and urine assays). Outcomes ESRD and all-cause mortality. Results In the CRIB cohort, 190 patients reached ESRD (12.1%/y) and 150 died (6.5%/y). Each 30% lower baseline estimated glomerular filtration rate was associated with a 3-fold higher ESRD rate and a 1.3-fold higher death rate. After adjustment for each other, only baseline creatinine level, serum phosphate level, urinary albumin-creatinine ratio, and female sex remained strongly (P < 0.01) predictive of ESRD. For death, age, N-terminal pro-brain natriuretic peptide, troponin T level, and cigarette smoking remained strongly predictive of risk. Using these factors to predict outcomes in the East Kent cohort yielded an area under the receiver operating characteristic curve (ie, C statistic) of 0.91 (95% CI, 0.87-0.96) for ESRD and 0.82 (95% CI, 0.75-0.89) for death. Limitations Other important factors may have been missed because of limited study power. Conclusions Simple laboratory measures of kidney and cardiac function plus age, sex, and smoking history can be used to help identify patients with CKD at highest risk of ESRD and death. Larger cohort studies are required to further validate these results.

[1]  C. McCulloch,et al.  Risk factors for end-stage renal disease: 25-year follow-up. , 2009, Archives of internal medicine.

[2]  C. Price,et al.  Prognostic value of cardiac biomarkers for death in a non-dialysis chronic kidney disease population. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  R. Glynn,et al.  Predicting outcomes in CKD. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[4]  O. Djurdjev,et al.  Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[5]  David H. Smith,et al.  Predicting the risk of dialysis and transplant among patients with CKD: a retrospective cohort study. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  B. Brenner,et al.  Renal risk scores: progress and prospects. , 2008, Kidney international.

[7]  Anders Larsson,et al.  Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. , 2008, The New England journal of medicine.

[8]  J. Coresh,et al.  Prevalence of chronic kidney disease in the United States. , 2007, JAMA.

[9]  J. Kaufman,et al.  Age affects outcomes in chronic kidney disease. , 2007, Journal of the American Society of Nephrology : JASN.

[10]  M. Landray,et al.  Cross-Sectional Analysis of Abnormalities of Mineral Homeostasis, Vitamin D and Parathyroid Hormone in a Cohort of Pre-Dialysis Patients , 2007, Nephron Clinical Practice.

[11]  M. Landray,et al.  CARDIOVASCULAR AND SURVIVAL PARADOXES IN DIALYSIS PATIENTS: Misleading Associations between Cholesterol and Vascular Outcomes in Dialysis Patients: The Need for Randomized Trials , 2007, Seminars in dialysis.

[12]  J. Griffith,et al.  The Framingham predictive instrument in chronic kidney disease. , 2007, Journal of the American College of Cardiology.

[13]  S de Lusignan,et al.  Chronic kidney disease management in the United Kingdom: NEOERICA project results. , 2007, Kidney international.

[14]  D. Kent,et al.  Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. , 2007, Journal of the American Society of Nephrology : JASN.

[15]  T. Hansen,et al.  N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population. , 2007, European heart journal.

[16]  R. Collins,et al.  N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study. , 2007, Journal of the American College of Cardiology.

[17]  F. Dekker,et al.  Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey , 2006, BMJ : British Medical Journal.

[18]  A. Tamakoshi,et al.  A scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[19]  Zhongxin Zhang,et al.  Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[20]  A. Garg,et al.  Chronic kidney disease and mortality risk: a systematic review. , 2006, Journal of the American Society of Nephrology : JASN.

[21]  G. Francis,et al.  Cardiac troponins and chronic kidney disease. , 2006, Kidney international.

[22]  C. Price,et al.  B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[23]  A. Dobson,et al.  How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review , 2005, BMJ : British Medical Journal.

[24]  A. Murray,et al.  Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. , 2005, Journal of the American Society of Nephrology : JASN.

[25]  C. Herzog,et al.  Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death. , 2004, Clinical chemistry.

[26]  C. Gullion,et al.  Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. , 2004, Archives of internal medicine.

[27]  M. Landray,et al.  Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[28]  R. Foley,et al.  Serum troponin T measurement in patients with chronic renal impairment predicts survival and vascular disease: a 2 year prospective study. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[29]  P. Stenvinkel,et al.  Elevated cardiac troponin T in predialysis patients is associated with inflammation and predicts mortality , 2003, Journal of internal medicine.

[30]  Fred S Apple,et al.  Predictive Value of Cardiac Troponin I and T for Subsequent Death in End-Stage Renal Disease , 2002, Circulation.

[31]  D C Wheeler,et al.  Epidemiological evaluation of known and suspected cardiovascular risk factors in chronic renal impairment. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[32]  David Roth,et al.  A simplified equation to predict glomerular filtration rate from serum creatinine , 2000 .

[33]  Colin Baigent,et al.  Premature cardiovascular disease in chronic renal failure , 2000, The Lancet.

[34]  M. Landray,et al.  Abnormalities of endothelial function in patients with predialysis renal failure , 2000, Heart.

[35]  D. Collett Modelling Survival Data in Medical Research , 1994 .

[36]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .

[37]  J. Hanley,et al.  The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.

[38]  R. Peto THE HORSE-RACING EFFECT , 1981, The Lancet.

[39]  B. Astor,et al.  Risk of incident ESRD: a comprehensive look at cardiovascular risk factors and 17 years of follow-up in the Atherosclerosis Risk in Communities (ARIC) Study. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[40]  David C. Murray,et al.  Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. , 1995, Kidney international.